Burden greater for psychological and somatic menopause symptoms, but not vasomotor symptoms
TUESDAY, Jan. 7, 2025 (HealthDay News) — Women living in rural areas may experience a greater burden of psychological and somatic menopause symptoms, according to a study published in the January issue of Menopause.
Erin R. Dwyer, from the University of Washington School of Medicine in Seattle, and colleagues compared menopause experience in rural-, suburban-, and urban-residing women. The analysis included online survey responses from 1,531 participants.
The researchers found that rural residents had more prevalent symptoms in late menopause transition, including muscle aches and pains (urban, 49 percent; suburban, 49 percent; rural, 65 percent) and panic attacks (urban, 18 percent; suburban, 24 percent; rural, 30 percent). Rural residents also had more prevalent symptoms in postmenopause, including: mood swings (urban, 18 percent; suburban, 14 percent; rural, 23 percent), urinary incontinence (urban, 19 percent; suburban, 14 percent; rural, 23 percent), and vaginal dryness (urban, 22 percent; suburban, 29 percent; rural, 37 percent). Overall, vasomotor symptom prevalence was high (71 percent late menopause transition, 20 percent postmenopause), while current menopause hormone therapy use was low (11 percent late menopause transition, 11 percent postmenopause) and did not differ by residence.
“Overall low rates of menopause hormone therapy use suggest a need for education regarding hormone therapy, tailored to residential groups who rely on different resources on healthy aging,” the authors write.
Two authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Estrogen Hormone Treatment May Be Beneficial for Brain Fog Symptoms in Menopausal Women
Menopausal Hormone Therapy Use Linked to Lower Risk for Alzheimer Disease
AMH Predicts Benefit of Chemo + Endocrine Therapy in Under 55s With Breast Cancer
Long-Term Medication Adherence Tied to Lower Cardiovascular Event Rate in Type 2 Diabetes
Add-On Tirzepatide May Reduce MACE Risk in People With T2D, ASCVD
Premature Menopause Linked to Increased Risk for Hypertension
Semaglutide Not Linked to Higher Neovascular Age-Related Macular Degeneration Risk